Innoviva, Inc. INVA Royalty — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Innoviva, Inc.'s royalty — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Innoviva, Inc.'s royalty — revenue?
- Innoviva, Inc. (INVA) reported royalty — revenue of $55.17M in Q1 2026.
- How has Innoviva, Inc.'s royalty — revenue changed year-over-year?
- Innoviva, Inc.'s royalty — revenue decreased by 4.6% year-over-year, from $57.81M to $55.17M.
- What is the long-term trend for Innoviva, Inc.'s royalty — revenue?
- Over 4 years (2021 to 2025), Innoviva, Inc.'s royalty — revenue has grown at a -11.9% compound annual growth rate (CAGR), from $391.87M to $236.48M.
- What does royalty — revenue mean?
- This represents the net income recognized from royalty-bearing assets after accounting for contract-related adjustments and excluding pass-through taxes. It serves as the primary indicator of the cash-generating capacity of the company's intellectual property portfolio. Monitoring this metric helps investors assess the performance and market demand for the underlying healthcare products licensed by the company.